We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease. Clinical Trials · Our Approach · News & Events · Imprint (Impressum)

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to ...

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros, including an upfront payment and additional ...

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart.

Cardior is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of innovative treatments for heart ...

25 мар. 2024 г. · Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics ...

25 мар. 2024 г. · Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain ...

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Cardior Pharmaceuticals, a leader in the discovery and development of RNA-based therapies for heart failure ...

25 сент. 2021 г. · Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based ...

26 мар. 2024 г. · Novo Nordisk announced that it has acquired Cardior Pharmaceuticals in hopes of improving its pipeline in cardiovascular disease management.